Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019

GAITHERSBURG, Md., March 11, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and year-end 2018 financial and operating results following the close of U.S. financial markets on Monday, March 18, 2019.

Conference call details are as follows:

Conference call and webcast replay:

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Its two priority programs are ResVax™, its RSV vaccine for infants via maternal immunization and NanoFlu™, its quadrivalent influenza nanoparticle vaccine. Novavax’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contact:

Investors
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000

Westwicke Partners
John Woolford
[email protected]
443-213-0506

Media
Sam Brown
Andrea Cohen
[email protected]
917-209-7163